Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes
Authors:
- Ernesto MaddaloniEMErnesto Maddaloni
- Rocco AmendolaraRARocco Amendolara
- Marco G. BaroniMBMarco G. Baroni
- Maria G. CavalloMCMaria G. Cavallo
- Massimiliano CopettiMCMassimiliano Copetti
- Efisio CossuECEfisio Cossu
- Luca D’oNofrioLDLuca D’oNofrio
- Salvatore De CosmoSCSalvatore De Cosmo
- Frida LeonettiFLFrida Leonetti
- Susanna MoranoSMSusanna Morano
Open Access
- 20 March 2023
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 39 (5) , e3632
Abstract
Background: Novel biomarkers of vascular disease in diabetes could help identify new mechanistic pathways. Osteocalcin, osteoprotegerin, and osteopontin are key molecules involved in bone and vascular calcification processes, both of which are compromised in diabetes. We aimed to evaluate possible associations of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease (CVD) and diabetic retinopathy (DR) among people with type 2 diabetes (T2D).Materials and Methods: Osteocalcin, osteoprotegerin, and osteopontin concentrations were measured at enrolment in 848 participants with T2D from the Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study (ClinicalTrials.gov: NCT02311244). Logistic regression models and propensity score matching were used to assess possible associations of osteocalcin, osteoprotegerin, and osteopontin with a history of CVD and with evidence of any grade of DR adjusting for confounders.Results: Previous CVD was reported in 139 (16.4%) participants, while 144 (17.0%) had DR. After adjusting for possible confounders, osteocalcin but not osteoprotegerin or osteopontin concentrations were associated with a history of CVD (Odds Ratio [OR] and 95% CI for one standard deviation (SD) increase in osteocalcin concentrations (natural log): 1.35 (1.06–1.72), p = 0.014). Associations with prevalent DR were seen for osteoprotegerin (OR for one SD increase in osteoprotegerin concentrations (natural log): 1.25 (1.01–1.55), p = 0.047) and osteopontin (OR for one SD increase in osteopontin concentrations (natural log): 1.25 (1.02–1.53), p = 0.022), but not osteocalcin.Conclusions: In T2D, higher serum osteocalcin concentrations are associated with macrovascular complications and higher osteoprotegerin and osteopontin concentrations with microvascular complications, suggesting that these osteokines might be involved in pathways directly related to vascular disease.Keywords
Funding Information
- Sapienza Università di Roma
- Ministero della Salute
- European Foundation for the Study of Diabetes
- Fondazione Diabete Ricerca
- National Institute for Health Research
This publication has 16 references indexed in Scilit:
- Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic RetinopathyOcular Immunology and Inflammation, 2017
- Serum levels of undercarboxylated osteocalcin are related to cardiovascular risk factors in patients with type 2 diabetes mellitus and healthy subjectsWorld Journal of Diabetes, 2017
- The “Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes”: Study protocolNutrition, Metabolism and Cardiovascular Diseases, 2016
- Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathyAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2014
- Serum levels of osteocalcin in relation to glucose metabolism and carotid atherosclerosis in Chinese middle-aged and elderly male adults: The Shanghai Changfeng StudyEuropean Journal of Internal Medicine, 2014
- Vascular Complications of Diabetes: Mechanisms of Injury and Protective FactorsCell Metabolism, 2013
- Osteoporosis—a risk factor for cardiovascular disease?Nature Reviews Rheumatology, 2012
- Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery DiseaseExperimental Diabetes Research, 2012
- Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular DiseaseCirculation, 2004
- Associations of Serum Osteoprotegerin Levels with Diabetes, Stroke, Bone Density, Fractures, and Mortality in Elderly Women1The Journal of Clinical Endocrinology & Metabolism, 2001